ABBV - CIK 0001551152
AbbVie Inc. trades as ABBV and has a market capitalization of $399.47 B, making it the #28 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $61.16B, up 8.6% from the prior year and net income of $4.23B. This page tracks AbbVie Inc. through 1,008 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years AbbVie Inc.'s revenue grew from $25.64B to $61.16B, a compound annual growth rate of 10.1%. Net profit margin compressed from 23.2% to 6.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
| Insider trade | 4 | 2026-05-12 |
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
AbbVie to Present at the Bank of America Securities Healthcare Conference
The largest companies sharing AbbVie Inc.'s SEC industry classification (pharmaceutical preparations).
AbbVie Inc. (ABBV) has a market capitalization of $399.47 B as of 2026-06-10, ranking #28 among US-listed companies.
AbbVie Inc. reported revenue of $61.16B for fiscal year 2025, an increase of 8.6% year over year.
Yes. AbbVie Inc. reported net income of $4.23B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.